Top

Published in:

01-05-2022 | Portal Vein Thrombosis | Review Article

Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies

Authors: D. Viñal, A. Minaya-Bravo, I. Prieto, J. Feliu, N. Rodriguez-Salas

Published in: Clinical and Translational Oncology | Issue 5/2022

Abstract

Transarterial radioembolization (TARE) with yttrium-90 (Y90) is a promising alternative strategy to treat liver tumors and liver metastasis from colorectal cancer (CRC), as it selectively delivers radioactive isotopes to the tumor via the hepatic artery, sparring surrounding liver tissue. The landscape of TARE indications is constantly evolving. This strategy is considered for patients with hepatocellular carcinoma (HCC) with liver-confined disease and preserved liver function in whom neither TACE nor systemic therapy is possible. In patients with liver metastases from CRC, TARE is advised when other chemotherapeutic options have failed. Recent phase III trials have not succeeded to prove benefit in overall survival; however, it has helped to better understand the patients that may benefit from TARE based on subgroup analysis. New strategies and treatment combinations are being investigated in ongoing clinical trials. The aim of this review is to summarize the clinical applications of TARE in patients with gastrointestinal malignancies.

Li H, Wu F, Duan M, Zhang G. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety. Med. 2019;98(21): e15314. https://doi.org/10.1097/MD.0000000000015314.CrossRef

Tr M, Or G. Hepatic artery catheterization for liver perfusion. Arch Surg. 1961;82(3):423–5. https://doi.org/10.1001/archsurg.1961.01300090093018.CrossRef

Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (y90 radiating microspheres). Ann Surg. 1965;162(2):267–78. https://doi.org/10.1097/00000658-196508000-00018.CrossRefPubMedPubMedCentral

Simon N, Warner R, Baron M, Rudavsky A. Intra-arterial irradiation of carcinoid tumors of the liver. Am J Roentgenol. 1968;102:552–61.CrossRef

Anderson JH, Angerson WJ, Willmott N, Kerr DJ, McArdle CS, Cooke TG. Regional delivery of microspheres to liver metastases: the effects of particle size and concentration on intrahepatic distribution. Br J Cancer. 1991;64:1031. https://doi.org/10.1038/bjc.1991.459.CrossRefPubMedPubMedCentral

Meade VM, Burton MA, Gray BN, Self GW. Distribution of different sized microspheres in experimental hepatic tumours. Eur J Cancer Clin Oncol. 1987;23:37–41. https://doi.org/10.1016/0277-5379(87)90416-0.CrossRefPubMed

Saini A, Wallace A, Alzubaidi S, et al. History and evolution of yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med. 2019. https://doi.org/10.3390/jcm8010055.CrossRefPubMedPubMedCentral

Gholam PM, Iyer R, Johnson MS. Multidisciplinary management of patients with unresectable hepatocellular carcinoma: a critical appraisal of current evidence. Cancers (Basel). 2019;11(6):873. https://doi.org/10.3390/cancers11060873.CrossRef

Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393–406. https://doi.org/10.1007/s00259-011-1812-2.CrossRefPubMed

10.

Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251–78.CrossRefPubMed

11.

Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefrac-tory liver metastases (HEPAR trial): a phase 1, dose-escalation study [published correction appears in Lancet Oncol. 2012 Nov;13(11):e464]. Lancet Oncol. 2012;13(10):1025–34. https://doi.org/10.1016/S1470-2045(12)70334-0.CrossRefPubMed

12.

Kavali PK, Gandhi RT. Suvranu Ganguli. Yttrium-90 radioembolization mapping and therapy. Endovasc Today. 2016;15(4):66–71.

13.

Klimkowski S, Baker JC, Brown DB. Red flags, pitfalls, and cautions in Y90 radiotherapy. Tech Vasc Interv Radiol. 2019;22(2):63–9. https://doi.org/10.1053/j.tvir.2019.02.005 (Epub 27 Feb 2019, PMID: 31079712).CrossRefPubMed

14.

Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198. https://doi.org/10.3389/fonc.2014.00198.CrossRefPubMedPubMedCentral

15.

Vogel A, Cervantes I, Chau B, Daniele J, Llovet T, Meyer J-C, Nault U, Neumann J, Ricke B, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–55.CrossRefPubMed

16.

The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28(3):751.

17.

Salem R, Gilbertsen M, Butt Z, et al. Increased quality of life among hepatocellular carcinoma patients treated with radio-embolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11(10):1358-1365.e1. https://doi.org/10.1016/j.cgh.2013.04.028.CrossRefPubMed

18.

Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci. 2008;53(9):2556–63. https://doi.org/10.1007/s10620-007-0148-z (Epub 2 008 Jan 31).CrossRefPubMed

19.

Titano J, Voutsinas N, Kim E. The role of radioembolization in bridging and downstaging hepatocellular carcinoma to curative therapy. Semin Nucl Med. 2019;49(3):189–96. https://doi.org/10.1053/j.semnuclmed.2019.01.003 (Epub 2019 Feb 23).CrossRefPubMed

20.

Teo JY, Goh BK, Cheah FK, Allen JC, Lo RH, Bg DC, et al. Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radia- tion therapy with 90Y in patients with hepatocellular carcinoma. J Digest Dis. 2014;15(8):444–50. https://doi.org/10.1111/1751-2980.12162.CrossRef

21.

Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remained in unresecable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029–36. https://doi.org/10.1016/j.jhep.2013.06.015 (Epub 25 Jun 2013).CrossRefPubMedPubMedCentral

22.

Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembo-lization. Int J Radiat Oncol Biol Phys. 2011;79(1):163–71. https://doi.org/10.1016/j.ijrobp.2009.10.062.CrossRefPubMed

23.

Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology–pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192.CrossRefPubMed

24.

Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21(9):1142–52. https://doi.org/10.1002/lt.24169.CrossRefPubMed

25.

Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, Gautam D, et al. Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging. Transplantation. 2020. https://doi.org/10.1097/TP.0000000000003162.CrossRefPubMed

26.

Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-1163.e2. https://doi.org/10.1053/j.gastro.2016.08.029.CrossRefPubMed

27.

Tohme S, Sukato D, Chen HW, Amesur N, Zajko AB, Humar A, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol. 2013;24(11):1632–8. https://doi.org/10.1016/j.jvir.2013.07.026.CrossRefPubMed

28.

Ettorre GM, Levi Sandri GB, Laurenzi A, Colasanti M, Meniconi RL, Lionetti R, et al. Yttrium-90 radioemboli-zation for hepatocellular carcinoma prior to liver transplantation. World J Surg. 2017;41(1):241–9. https://doi.org/10.1007/s00268-016-3682.CrossRefPubMed

29.

Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florián SS, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within milan criteria undergoing liver trans-plantation: analysis of 3601 patients from the US Multicenter HCC Transplant Consortium. Ann Surg. 2017;266(3):525–35. https://doi.org/10.1097/SLA.0000000000002381.CrossRefPubMed

30.

Lobo L, Yakoub D, Picado O, Ripat C, Péndola F, Sharma R, et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2016;39:1580–8. https://doi.org/10.1007/s00270-016-1426-y.CrossRefPubMed

31.

Ludwig JM, Zhang D, Xiong M, Kim HS. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. Eur Radiol. 2017;27(5):2031–41. https://doi.org/10.1007/s00330-016-4548-3.CrossRefPubMed

32.

Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507.CrossRefPubMed

33.

Kumasi A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, et al. 2019 Update of indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in india: the Puri II Recommendations. J Clin Exp Hepatol. 2020;10(1):43–80. https://doi.org/10.1016/j.jceh.2019.09.007 (Epub 23 Sep 2019).CrossRef

34.

Riaz A, Gabr A, Abouchaleh N, et al. Radioembolization for hepatocellular carcinoma: statistical confirmation of improved survival in responders by landmark analyses. Hepatology. 2018;67:873–83.CrossRefPubMed

35.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma [published correction ap-pears in J Hepatol. 2019 Apr;70(4):817]. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019

36.

Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522–9.CrossRefPubMed

37.

Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, Courtney A. Use of Yttrium-90 glass micro-spheres (therasphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15:335–45. https://doi.org/10.1097/01.RVI.0000123319.20705.92.CrossRefPubMed

38.

Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A, Nemcek AA, Gates VL, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81. https://doi.org/10.1002/hep.21980.CrossRefPubMed

39.

Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64. https://doi.org/10.1053/j.gastro.2009.09.006.CrossRefPubMed

40.

Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57:1826–37. https://doi.org/10.1002/hep.26014.CrossRefPubMed

41.

Pracht M, Edeline J, Lenoir L, Latournerie M, Mesbash AO, et al. Ipsilateral portal vein tumor thrombosis treated with Yttrium-90 glass microbes-here radioembolization: preliminary results. Int J Hepatol. 2013. https://doi.org/10.1155/2013/827649.CrossRefPubMedPubMedCentral

42.

She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, et al. Survival analysis of transarterial radioembolization with Yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr. 2014;3:185–93.PubMedPubMedCentral

43.

Somma F, Stoia V, Serra N, D’Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS ONE. 2019;14(5):e0216935.CrossRefPubMedPubMedCentral

44.

Cardarelli-Leite L, Chung J, Klass D, et al. Ablative transarterial radioembolization improves survival in patients with HCC and portal vein tumor thrombus. Cardiovasc Intervent Radiol. 2020;43(3):411–22. https://doi.org/10.1007/s00270-019-02404-5.CrossRefPubMed

45.

Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosidad C, et al. J Hepatol. 2018;68(4):724–32. https://doi.org/10.1016/j.jhep.2017.12.026.CrossRefPubMed

46.

Kim PH, Choi SH, Kim JH, Park SH. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy. Korean J Radiol. 2019;20(3):385–98. https://doi.org/10.3348/kjr.2018.0496.CrossRefPubMedPubMedCentral

47.

Viagrain V, Pereira H, Assenat E, Guiu B, Llonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet oncol. 2017;18(12):1624–36. https://doi.org/10.1016/S1470-2045(17)30683-6.CrossRef

48.

Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21. https://doi.org/10.1200/JCO.2017.76.0892.CrossRefPubMed

49.

Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–74. https://doi.org/10.1016/j.jhep.2019.08.006.CrossRefPubMed

50.

Venerito M, Pech M, Canbay A, et al. NEMESIS: noninferiority, individual-patient metaanalysis of selective internal radi-ation therapy with 90Y resin microspheres versus sorafenib in advanced hepatocellular carcinoma. J Nucl Med. 2020;61(12):1736–42. https://doi.org/10.2967/jnumed.120.242933.CrossRefPubMed

51.

Chauhan N, Bukovcan J, Boucher E, et al. Intra-Arterial theraSphere Yttrium-90 glass microspheres in the treatment of patients with unresectable hepatocellular carcinoma: protocol for the STOP-HCC Phase 3 randomized controlled trial. JMIR Res Protoc. 2018;7(8):e11234. https://doi.org/10.2196/11234.CrossRefPubMedPubMedCentral

52.

Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438–50. https://doi.org/10.1097/01.sla.0000138076.72547.b1.CrossRefPubMedPubMedCentral

53.

Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemo-therapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85.CrossRefPubMed

54.

van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cáncer [published correction appears in J Clin Oncol. 2016 Nov 20;34(33):4059]. J Clin Oncol. 2016;34(15):1723–31. https://doi.org/10.1200/JCO.2015.66.1181.CrossRefPubMed

55.

Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71. https://doi.org/10.1016/S1470-2045(17)30457-6.CrossRefPubMedPubMedCentral

56.

Wolsenholme J, Fusco F, Gray AM, Moschandreas J, Virdee PS, Love S, et al. Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-globa; Randomised trials of selective internal radiotherapy for metastatic colorectal cancer. Int J Cancer. 2019. https://doi.org/10.1002/ijc.32828.CrossRef

57.

Gibbs P, Heinemann V, Sharma NK, et al. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies. Clin Colorectal Cancer. 2018;17(4):e617–29. https://doi.org/10.1016/j.clcc.2018.06.001.CrossRefPubMed

58.

Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumor localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69–80. https://doi.org/10.1016/j.ejca.2017.07.016.CrossRefPubMedPubMedCentral

59.

Wasan H, Sharma R, Heinemann V, et al. FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis. Ann Oncol. 2017;28:v615.CrossRef

60.

Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter Phase III Trial [published online ahead of print, 2021 Sep 20]. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.01839.CrossRefPubMed

61.

Rostambeigi N, Dekarske AS, Austin EE, et al. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25:1075–84.CrossRefPubMed

62.

Lentz RW, Messersmith WA. Transarterial radioembolization in patients with unresectable colorectal cancer liver me-tastases [published online ahead of print, 2021 Sep 20]. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.01993.CrossRefPubMed

63.

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. https://doi.org/10.1093/annonc/mdw235.CrossRefPubMed

64.

Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lam-bert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colo-rectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687–94.CrossRefPubMed

65.

Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg. 1992;62(2):105–10. https://doi.org/10.1111/j.1445-2197.1992.tb00006.x.CrossRefPubMed

66.

Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unre-sectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103(3):324–31. https://doi.org/10.1038/sj.bjc.6605770.CrossRefPubMedPubMedCentral

67.

Cianni R, Urigo C, Notarianni E, et al. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med. 2010;115(4):619–33. https://doi.org/10.1007/s11547-010-0496-1.CrossRefPubMed

68.

Sofocleous CT, Violari EG, Sotirchos VS, et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer. 2015;14(4):296–305. https://doi.org/10.1016/j.clcc.2015.06.003.CrossRefPubMedPubMedCentral

69.

Lewandowski RJ, Memon K, Mulcahy MF, et al. Twelve-year experience of radioembolization for colorectal hepatic metas-tases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1861–9. https://doi.org/10.1007/s00259-014-2799-2.CrossRefPubMed

70.

Kennedy A, Cohn M, Coldwell DM, et al. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases [published correction appears in J Gastrointest Oncol. 2018 Apr;9(2):E13-E14]. J Gastrointest Oncol. 2017;8(4):614–24. https://doi.org/10.2103/jgo.2017.03.10.CrossRefPubMedPubMedCentral

71.

Case MD, Ghodadra A, Novelli PM, et al. KRAS status and survival in multicenter study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment. J Clin Oncol. 2020. https://doi.org/10.1097/SLA.0b013e3182a5025a.CrossRef

72.

Lahti SJ, Xing M, Zhang D, et al. kras status as an independent prognostic factor for survival after yttrium-90 radioemboli-zation therapy for unresectable colorectal cancer liver metastases. J Vasc Interv Radiol. 2015;26:1102–11.CrossRefPubMed

73.

Magnetta MJ, Ghodadra A, Lahti SJ, et al. Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Abdom Radiol (NY). 2017;42:451–9.CrossRef

74.

Bester L, Meteling B, Pocock N, et al. Radioembolization versus standard care of hepatic metastases: comparative retro-spective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2012;23:96–105.CrossRefPubMed

75.

Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2012;35:1066–73.CrossRefPubMed

76.

Fahmueller YN, Nagel D, Hoffmann RT, et al. Predictive and prognostic value of circulating nucleosomes and serum bi-omarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer. 2012;12:5.CrossRefPubMedPubMedCentral

77.

Fahmueller YN, Nagel D, Hoffmann RT, et al. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer. 2013;132:2349–58.CrossRefPubMed

78.

Carpizo DR, Gensure RH, Yu X, et al. Pilot study of angiogenic response to yttrium-90 radioembolization with resin mi-crospheres. J Vasc Interv Radiol. 2014;25:297-306.e1.CrossRefPubMed

79.

Tohme S, Sukato D, Chalhoub D, et al. Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of sur-vival after radioembolization for metastatic colorectal cancer. Ann Surg Oncol. 2015;22:1701–2170.CrossRefPubMed

80.

de Baere T, Tselikas L, Yevich S, et al. The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer. 2017;75:231–42. https://doi.org/10.1016/j.ejca.2017.01.010.CrossRefPubMed

81.

Campbell SR, Balagamwala EH, Woody NM, Stephans KL. Multimodality management of colorectal liver oligometastases. Appl Rad Oncol. 2019;8(3):9–16.

82.

Ray CE, Edwards A, Smith MT. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2013;24(8):1218–26.CrossRefPubMed

83.

Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015;41(1):120–7. https://doi.org/10.1016/j.ejso.2014.09.007.CrossRefPubMedPubMedCentral

84.

Roayaie S, Guarrera JV, Ye MQ, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of out-comes. J Am Coll Surg. 1998;187(4):365–72. https://doi.org/10.1016/s1072-7515(98)00203-8.CrossRefPubMed

85.

Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. https://doi.org/10.1056/NEJMoa0908721.CrossRefPubMed

86.

Mouli S, Memon K, Baker T. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.CrossRefPubMedPubMedCentral

87.

Martinez BK, Flanders V, Gupta NK, Natarajan K, Underhill MP, Cooke J. Development of a Y90 radioembolization program in a community hospital setting for treatment of metastatic and primary liver tumors. J Vasc Interv Radiol. 2013;24(5):759.e32-759.e33.

88.

Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J. A pooled analysis of transarterial radioembolization with yttrium-90 mi-crospheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther. 2019;12:4489–98. https://doi.org/10.2147/OTT.S202875.CrossRefPubMedPubMedCentral

89.

White J, Carolan-Rees G, Dale M, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahe-patic cholangiocarcinoma: a prospective, Observational Study. J Vasc Interv Radiol. 2019;30(8):1185–92. https://doi.org/10.1016/j.jvir.2019.03.018.CrossRefPubMed

90.

Akinwande O, Shah V, Mills A, et al. Chemoembolization versus radioembolization for the treatment of unresectable in-trahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity. Hepat Oncol. 2017;4(3):75–81. https://doi.org/10.2217/hep-2017-0005.CrossRefPubMedPubMedCentral

91.

Mosconi C, Solaini L, Vara G, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis. Cardiovasc Intervent Radiol. 2021;44(5):728–38. https://doi.org/10.1007/s00270-021-02800-w.CrossRefPubMed

92.

Köhler M, Harders F, Lohöfer F, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with Yttrium-90 radioembolization. J Clin Med. 2019;9(1):56. https://doi.org/10.3390/jcm9010056.CrossRefPubMedCentral

93.

Nezami N, Camacho JC, Kokabi N, El-Rayes BF, Kim HS. Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin. J Gastrointest Oncol. 2019;10(5):944–56. https://doi.org/10.21037/jgo.2019.05.10.CrossRefPubMedPubMedCentral

94.

Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):51–9. https://doi.org/10.1001/jamaoncol.2019.3702.CrossRefPubMed

95.

Helmberger T, Golfieri R, Pech M, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35. https://doi.org/10.1007/s00270-020-02642-y.CrossRefPubMed

96.

Kim AY, Frantz S, Brower J, Akhter N. Radioembolization with Yttrium-90 microspheres for the treatment of liver metastases of pancreatic adenocarcinoma: a multicenter analysis. J Vasc Interv Radiol. 2019;30(3):298-304.e2. https://doi.org/10.1016/j.jvir.2018.09.020.CrossRefPubMed

97.

Kayaleh R, Krzyston H, Rishi A, et al. Transarterial radioembolization treatment of pancreatic cancer patients with liver-dominant metastatic disease using Yttrium-90 glass microspheres: a single-institution retrospective study. J Vasc Interv Radiol. 2020;31(7):1060–8. https://doi.org/10.1016/j.jvir.2019.11.037.CrossRefPubMed

98.

Cao C, Yan TD, Morris DL, Bester L. Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study. Tumori. 2010;96(6):955–8.CrossRefPubMed

99.

Michl M, Haug AR, Jakobs TF, et al. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Oncology. 2014;86(1):24–32. https://doi.org/10.1159/000355821.CrossRefPubMed

100.

Kim AY, Unger K, Wang H, Pishvaian MJ. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience. BMC Cancer. 2016;16:492. https://doi.org/10.1186/s12885-016-2552-2.CrossRefPubMedPubMedCentral

101.

Kennedy A, Bester L, Salem R, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumors (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17(1):29–37. https://doi.org/10.1111/hpb.12326.CrossRef

102.

Nigri G, Petrucciani N, Debs T, et al. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142. https://doi.org/10.1186/s12957-018-1446-y.CrossRefPubMedPubMedCentral

103.

Delle Fave G, O’Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neo-plasms. Neuroendocrinology. 2016;103(2):119–24. https://doi.org/10.1159/000443168.CrossRefPubMed

104.

Egger ME, Armstrong E, Martin RC 2nd, et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis. J Am Coll Surg. 2020;230(4):363–70. https://doi.org/10.1016/j.jamcollsurg.2019.12.026.CrossRefPubMed

105.

Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol. 2018;100:23–9. https://doi.org/10.1016/j.ejrad.2018.01.012.CrossRefPubMed

Title: Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies
Authors: D. Viñal
A. Minaya-Bravo
I. Prieto
J. Feliu
N. Rodriguez-Salas
Publication date: 01-05-2022
Publisher: Springer International Publishing
Keywords: Portal Vein Thrombosis
Metastasis
Hepatocellular Carcinoma
Portal Vein Thrombosis
Hepatocellular Carcinoma
Sorafenib
Colorectal Cancer
Colorectal Cancer
Published in: Clinical and Translational Oncology / Issue 5/2022
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-021-02745-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2022

Quantitative assessments of late radiation-induced skin and soft tissue toxicity and correlation with RTOG scales and biological equivalent dose in breast cancer

Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis

Silencing IKBKE inhibits the migration and invasion of glioblastoma by promoting Snail1 degradation

Minimally invasive surgery for pediatric dumbbell neuroblastoma: systematic literature review and report of a single-stage neurosurgical and thoracoscopic approach

Bone marrow mesenchymal stem cells promote the progression of prostate cancer through the SDF-1/CXCR4 axis in vivo and vitro

STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer